Product nameAnti-HOXA9 antibody [EPR3655(2)]
See all HOXA9 primary antibodies
DescriptionRabbit monoclonal [EPR3655(2)] to HOXA9
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC or IHC-P
Species reactivityReacts with: Human
Synthetic peptide within Human HOXA9 aa 250 to the C-terminus (C terminal). The exact sequence is proprietary.
- HepG2, Human thymus, U937, SW480 and 293T lysates; HepG2 cells.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 0.05% BSA, 59% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab140631 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 30 kDa.|
FunctionSequence-specific transcription factor which is part of a developmental regulatory system that provides cells with specific positional identities on the anterior-posterior axis.
Involvement in diseaseNote=A chromosomal aberration involving HOXA9 is found in a form of acute myeloid leukemia. Translocation t(7;11)(p15;p15) with NUP98.
Note=A chromosomal aberration involving HOXA9 may contribute to disease progression in chronic myeloid leukemia. Translocation t(7;17)(p15;q23) with MSI2.
Sequence similaritiesBelongs to the Abd-B homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
FormHOXA9 is a transcription factor with a central role in both haemopoiesis and leukaemia. High levels of HOXA9 expression in haemopoietic cells is a characteristic feature of acute myeloid leukaemia (AML), and may be sufficient to cause this disease. Overexpression of Hoxa 9 markedly expands hematopoietic stem cells.
- ABD-B antibody
- Abd-B, drosophila, homolog of antibody
- D6a9 antibody
All lanes : Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 1/2000 dilution (purified)
Lane 1 : HepG2 whole cell lysate
Lane 2 : Human thymus lysate
Lane 3 : U937 whole cell lysate
Lane 4 : HEK293 whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 30 kDa
Observed band size: 30 kDa
Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
All lanes : Anti-HOXA9 antibody [EPR3655(2)] (ab140631) at 1/1000 dilution (Unpurified)
Lane 1 : HepG2 cell lysate
Lane 2 : Human thymus tissue lysate
Lane 3 : U937 cell lysate
Lane 4 : SW480 ell lysate
Lane 5 : 293T cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 30 kDa
This product has been referenced in:
- Li C et al. Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica 105:148-160 (2020). Read more (PubMed: 30975912) »
- Minuesa G et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun 10:2691 (2019). Read more (PubMed: 31217428) »